Merry Christmas and a Happy New Year
The year 2023 is slowly coming to an end. Therefore, as usual at this point, I would like to wish my readers a blessed Christmas season, as well as luck and health for the coming
Continue reading
Category: Therapy for MS
Autologous Hematopoietic Stem Cell Transplantation (aHSCT) – Results from the Swedish MS Registry
In September 2023, a paper from Sweden was published in the Journal of Neurology Neurosurgery and Psychiatry (JNNP) (Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study |
Continue reading
Frexalimab – Results of the Phase II Study and their Significance
This is about a B-cell inhibitor called Frexalimab. It is still in the pipeline and is being tested against MS. When it comes to new therapeutic strategies for the treatment of multiple sclerosis, the influence
Continue reading
MS and other Autoimmune Diseases
“An autoimmune disease rarely comes alone” – this is a saying from medical school that certainly has its validity. Since MS is an autoimmune disease, it is not surprising that one can observe a cluster
Continue reading
Side Effect of MS Medications: Ocrelizumab
Ocrelizumab (Ocrevus®) is a monoclonal antibody and belongs to the group of so-called B-cell-depleting therapies, which currently play a very important role in the immunotherapy of Multiple Sclerosis. They are used quite frequently. This article
Continue reading
Neural Stem Cells in Progressive MS
This is about neural stem cells in progressive MS. Be careful, there is a risk of confusion: I had already taken a stance on stem cell therapy in the DocBlog (see DocBlog from 25.10.2019) –
Continue reading
Immunoglobulin Levels and B-Cell Depletion (2)
What to do when immunoglobulin levels are lowered by B-cell depletion? – In the first post on this topic, I outlined how important B-cell-depleting therapies are for the treatment and stabilization of especially (highly) active
Continue reading Immunoglobulin Levels and B-Cell Depletion (1)
B-cell depleting therapies such as Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta) or the newly approved Inebilizumab (Uplizna) for the treatment of NMOSD are currently very important tools for controlling active MS courses and for preventing relapses in
Continue reading
ECTRIMS 2022 (1) – Highly Effective Therapies
Finally back in person! After the meeting of the European Committee for Therapy and Research in Multiple Sclerosis (ECTRIMS) was held virtually due to the pandemic over the last two years, MS experts from all
Continue reading News on the Therapy of Acute MS Flares
While there have been frequent updates about long-term immunotherapy for MS recently, the approach to treating MS relapses has remained unchanged for years. The treatment of acute MS relapses typically involves a high-dose corticosteroid preparation
Continue reading
